Gilead Sciences

Gilead Sciences Acquires Ouro Medicines for $1.675 Billion to Expand Autoimmune Therapy Portfolio

Galapagos

Gilead's $2.2bn Acquisition of Ouro Medicines Marks Entry into T-Cell Engager Space

Gilead Sciences to Acquire Ouro Medicines, Expanding Autoimmune Therapy Portfolio with OM336 Bispecific T Cell Engager

Gilead Sciences to Acquire Ouro Medicines for $2.2 Billion, Bolstering Autoimmune Portfolio.

Gilead Sciences Acquires Ouro Medicines for $2.18 Billion, Boosts Inflammation Portfolio

Catalyst<ul> <li>Most analysts rate GILD Buy or Strong Buy, showing broad institutional optimism.</li> <li>The company maintains strong cash reserves relative to market value.</li> <li>Recent Bullish bias signals from RSI Overbought in early February suggest potential rebound momentum.</li></ul>Risk<ul> <li>Fund flow trends show negative net outflows in Large and Extra-large order sizes, indicating institutional caution.</li> <li>MACD Death Cross signal on February 19 introduces uncertainty about technical direction.</li> <li>Technical indicators show that the market is in a volatile state, and the direction is not clear enough.</li></ul>

Key Factors

Gilead Sciences (GILD) agreed to acquire Ouro Medicines for up to $2.18 billion to bolster its autoimmune and inflammation portfolio. The acquisition includes Ouro's clinical-stage drug gamgertamig, which has Fast Track and Orphan Drug Designation from the FDA and is expected to enter registrational studies in 2027. Gilead will pay $1.675 billion upfront in cash and up to $500 million in contingent milestone payments, making this its second major acquisition in immunology this year. Galapagos NV is in advanced talks with Gilead to co-develop gamgertamig, potentially funding half of the upfront and milestone payments.

GILD News